What a Customs Hold Is Really Costing Your Medical Device Supply Chain

Most medical device operations leaders know that customs holds are expensive. What very few of them have done is actually run the numbers. That gap is exactly where medical device supply chain risk tends to hide. A customs hold is a carrying cost event with measurable financial consequences across capital, storage, risk, and opportunity cost dimensions.The math is worth understanding before your next shipment gets flagged.

The Cost That Doesn’t Show Up on the Invoice

When operations and procurement teams evaluate the economics of offshore sourcing, the analysis almost always centers on unit price. What that analysis consistently leaves out is the carrying cost exposure that comes with every shipment that has to clear U.S. Customs and Border Protection, FDA regulatory screening, and an increasingly complex medical device import compliance landscape.

That exposure doesn’t appear on any supplier invoice, which is precisely why it so rarely gets factored into true landed cost calculations until the damage is already done.

Inventory carrying costs are rarely applied as a framework to customs delays in the medical device supply chain. Most organizations treat a hold as a binary event, but it’s smarter to view it as a meter that starts running the moment a container is flagged, accumulating real costs across multiple categories for every day it sits.

Those who have already worked through the full cost picture often find that offshore medical device manufacturing looks considerably more expensive once carrying cost exposure is included.

Why Medical Device Shipments Get Held

Before quantifying what a hold costs, it helps to understand why they happen, because the triggers are specific to medical device import compliance in ways that make this industry significantly more hold-prone than general manufacturing. Medical devices face a layered regulatory gauntlet that general commercial freight does not, and the documentation requirements alone create multiple points of failure that can stop a shipment cold.

Documentation Errors and HS Code Misclassification

Harmonized System (HS) code misclassification is one of the most common hold triggers for medical device shipments, and it’s more consequential here than in most other industries. The wrong HS code can trigger an incorrect regulatory screening pathway, create mismatches between declared product classifications and FDA registration records, and route a shipment into manual review that might otherwise have been cleared automatically.

FDA Screening and Regulatory Compliance Flags

Every medical device import shipment entering the U.S. is processed through the FDA’s PREDICT system that assigns each entry a score based on product type, manufacturer history, country of origin, and documentation accuracy. Shipments that score above a certain threshold are flagged for examination, ranging from a records review to a full physical inspection. Even a single discrepancy in labeling, UDI compliance, or prior violation history can elevate a risk score and add days to the clearance timeline.

Detention Without Physical Examination

The most severe hold scenario in medical device supply chain management is Detention Without Physical Examination (DWPE), which the FDA can impose on any shipment from a manufacturer with a documented history of violations or quality system failures. Under DWPE, future shipments are automatically detained regardless of contents. Once triggered, the importer typically has ten business days to provide documentation sufficient to release the goods, after which the FDA can formally refuse the shipment and require export or destruction.

What a Customs Hold Actually Costs

Inventory carrying costs make up a significant total of inventory value annually, with medical device manufacturing trending higher. Applied to a customs hold, that annual rate becomes a daily compounding cost. Four components drive this cost:

Capital costs. The largest cost component is the capital tied up in the shipment itself. At a 20 percent annual carrying rate, a $500,000 shipment held for 30 days generates roughly $8,200 in capital cost alone. When balancing quality with cost in medical device production, every dollar immobilized at port is a dollar unavailable for production, R&D, or working capital.
Storage and demurrage fees. While a container waits at port, demurrage and detention charges accumulate. Holds stretching into weeks can generate storage costs that rival or exceed the original freight expense, particularly for temperature-sensitive or sterility-critical devices requiring controlled storage conditions throughout the hold.
Inventory risk like obsolescence and sterility exposure. This is where medical device supply chain risks diverge most sharply from general manufacturing. A sterilized device with a defined sterility assurance period that spends 45 days in customs is not the same product it was when it shipped. An extended hold can trigger a requalification requirement that transforms a delayed shipment into a destroyed one.
Opportunity costs. Beyond direct financial costs sit the revenue not generated because product isn’t available to ship, the customer commitments that can’t be met, and the launch timelines that slip. For a medical device contract manufacturer or OEM managing tight hospital system contracts, a hold that delays delivery by two to three weeks can trigger penalty clauses and erode relationships that took years to build.

Remington Medical’s contract manufacturing services are built to keep production, compliance, and delivery coordination under one roof, so the customs risk that offshore relationships carry isn’t part of the equation.

Learn More

What This Means for How You Evaluate Offshore Manufacturing

True landed cost is a concept most supply chain leaders nod to in principle but rarely operationalize? It’s straightforward to account for unit price, freight, and duties. It’s considerably more difficult to model the probabilistic carrying cost exposure that comes with every shipment clearing a complex medical device import compliance process.

The result is that most offshore sourcing decisions are made on a landed cost calculation that systematically understates actual cost, and the gap tends to widen as hold frequency accumulates and medical device supply chain risk compounds over time. Scaling from prototype to full production is a major investment, and the sourcing assumptions built into the original business case rarely include a realistic carrying cost line for customs exposure.

The practical implication is that any serious evaluation of an offshore manufacturing relationship should include a carrying cost scenario analysis. That analysis won’t always favor domestic manufacturing, but it will produce a more honest comparison. The topics worth discussing with any contract manufacturer include customs compliance track record, documentation management practices, and the degree to which the relationship reduces or amplifies carrying cost risk.

The medical device supply chain decisions that hold up over time are the ones built on the full number, not just the unit price.

Start Shipping With a More Complete Cost Picture

If your current landed cost analysis doesn’t include a carrying cost line for customs exposure, it’s underestimating what offshore sourcing actually costs your organization. Remington Medical works with OEMs who are ready to build a manufacturing relationship around the full picture.

Reach out to our team to talk through your current sourcing structure and what a more complete cost analysis might reveal.